In a matched cohort analysis of >12,000 patients initiating empagliflozin or metformin in a real-world setting, SGLT-2 inhibition conferred a 25% lower hazard for AF diagnosis [65]. The gene discussed is SLC5A2; the disease is atrial fibrillation.